Zegfrovy 150 mg Tablet

Description

Zegfrovy 150 mg Tablet contains Sunvozertinib, a next-generation EGFR tyrosine kinase inhibitor (TKI) developed to specifically target EGFR exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC).

Traditional EGFR inhibitors show limited efficacy against exon 20 insertion mutations, but Sunvozertinib has demonstrated strong clinical results, improving response rates and survival outcomes in previously treated patients. It works by selectively inhibiting mutant EGFR kinase activity, thereby blocking cancer cell proliferation and tumor growth.

Medical Uses of Zegfrovy 150 mg:

• Treatment of EGFR exon 20 insertion-positive NSCLC

• For adult patients with locally advanced or metastatic disease

• Effective in patients who have progressed on prior chemotherapy or EGFR therapy

Key Benefits:

• Advanced targeted therapy for resistant EGFR mutations

• Improved tumor response and progression-free survival

• Designed to overcome limitations of first- and second-generation TKIs

• Convenient once-daily oral dosing

How to Use:
The recommended dose of Zegfrovy is 150 mg orally once daily, with or without food, or as directed by the treating oncologist.

Possible Side Effects:
Diarrhea, rash, nausea, fatigue, decreased appetite, and elevated liver enzymes. Serious but less common effects include interstitial lung disease and heart rhythm disturbances.

FAQs :
No schema found.